

International Society of Drug Bulletins

Disclosure of competing interests

A key role of ISDB is to prepare and disseminate high-quality, unbiased drug information. This requires independence from the pharmaceutical industry, It is thus vital that ISDB bulletins recognise and effectively manage competing interests, both real and perceived.¹

Bulletins may already have policies on conflict of interest, but to assist those which do not and those which want to improve their policies, ISDB has produced forms for disclosing conflict of interest These forms are adapted from those of the International Committee of Medical Journal Editors.² They are designed to provide readers and ISDB with information regarding the extent to which bulletin content can be seen to be independent of commercial and other biases. The forms are to be completed, stored by the bulletin and should be publicly available .

The chief editor of each member bulletin is responsible for providing information about financial support for the bulletin (Form A). The chief editor may also collect individual returns from staff members (Form B) and from external authors and reviewers (Form C). Form B is to be updated annually. Since competing interests may vary according to topic, Form C for external authors (and reviewers) needs to be completed for each article considered for publication.

1 <http://www.plosmedicine.org/static/competing.action>

2 Adapted from http://www.icmje.org/ethical_4conflicts.html

International Society of Drug Bulletins

Form A: Disclosure of competing interests for the bulletin

Institutional links of interest and financial support for the bulletin

The chief editor of the bulletin is responsible for the completion of this form. It is recommended that this is done once a year.

Name of Bulletin	Pharma-Brief
Country	Germany
Email	pharma-brief@bukopharma.de
Chief Editor	Jörg Schaaber
Editorial team	Claudia Jenkes, Max Klein

Date of completion of this form 1 October 2019

Income of the bulletin

The bulletin is paid for by subscriptions. Additional funding comes from BUKO Pharma-Kampagne. The organisation is financed by public funds, charitable foundations and private donations. More information: www.bukopharma.de/index.php/de/wir-ueber-uns/transparenzerklaerung BUKO Pharma-Kampagne does not accept donations from the healthcare industry.

The editorial team is employed by BUKO Pharma-Kampagne. A competing interest policy is part of the contract of employment. It does prohibit to take money from the healthcare industry.

External authors are asked to fill in a disclosure form.